hVIVO Yönetim

Yönetim kriter kontrolleri 4/4

hVIVO CEO'su Mo Khan, Feb2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı £ 621.00K olup, şirket hissesi ve opsiyonları dahil olmak üzere 49% maaş ve 51% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.077% ine doğrudan sahiptir ve bu hisseler € 125.43K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 3.5 yıldır.

Anahtar bilgiler

Mo Khan

İcra Kurulu Başkanı

UK£621.0k

Toplam tazminat

CEO maaş yüzdesi	49.0%
CEO görev süresi	2.8yrs
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	2.8yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Mo Khan'un ücretlendirmesi hVIVO'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	UK£17m
Mar 31 2024	n/a	n/a	UK£17m
Dec 31 2023	UK£621k	UK£304k	UK£16m
Sep 30 2023	n/a	n/a	UK£9m
Jun 30 2023	n/a	n/a	UK£3m
Mar 31 2023	n/a	n/a	UK£1m
Dec 31 2022	UK£592k	UK£260k	-UK£776k

Tazminat ve Piyasa: Mo 'ın toplam tazminatı ($USD 780.42K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 786.80K ).

Tazminat ve Kazançlar: Mo 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Mo Khan (55 yo)

2.8yrs

Görev süresi

UK£621,000

Tazminat

Dr. Yamin Mohammed Khan, also known as Mo, serves as Chief Executive Officer at hVIVO plc (formerly known as Open Orphan Plc) since February 24, 2022 and also serves as its Director since 2022. He was Inde...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yamin Khan	CEO & Director	2.8yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	Veri yok
Andrew Catchpole	Chief Scientific Officer	no data	Veri yok	Veri yok
Teja Marathe-Sarvadikar	Head of QA	2.8yrs	Veri yok	Veri yok

2.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: CRO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yamin Khan	CEO & Director	3.1yrs	UK£621.00k	0.077% € 125.4k
Stephen Pinkerton	CFO & Executive Director	2.1yrs	UK£274.00k	Veri yok
Brendan Buckley	Member of Advisory Board & Non-Executive Director	no data	UK£45.00k	0.59% € 962.1k
Cathal Friel	Chairman of the Board	4.8yrs	UK£216.00k	Veri yok
Martin Gouldstone	Independent Non-Executive Director	2.4yrs	UK£45.00k	Veri yok
Elaine Sullivan	Independent Non-Executive Director	4yrs	UK£45.00k	Veri yok
John Oxford	Chair of Advisory Board	4.8yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: CRO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

hVIVO Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

hVIVO plc, Annual General Meeting, May 13, 2024

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Less than half of directors are independent

Recent updates

hVIVO plc to Report First Half, 2024 Results on Sep 10, 2024

hVIVO Proposes Cancellation of Admission to Trading on Euronext Growth

hVIVO plc, Annual General Meeting, May 13, 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings released: EPS: UK£0.024 (vs UK£0.001 loss in FY 2022)

hVIVO plc to Report Fiscal Year 2023 Results on Apr 09, 2024

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

hVIVO plc has completed a Follow-on Equity Offering in the amount of £8.38745 million.

Now 22% undervalued

hVIVO plc Signs £6.3 Million Human Challenge Study Model

hVIVO plc Increases Revenue Guidance for 2023

hVIVO plc to Report First Half, 2023 Results on Sep 12, 2023

hVIVO plc to Develop Human Metapneumovirus Challenge Model

Full year 2022 earnings released: UK£0.001 loss per share (vs UK£0 in FY 2021)

Forecast to breakeven in 2023

hVIVO plc Provides Earnings Guidance for the Full Year 2022

Forecast breakeven date pushed back to 2023

hVIVO plc Announces Publication of Imutex Phase I Data

Now 20% undervalued

Less than half of directors are independent

Open Orphan plc Announces Chief Financial Officer Changes

Open Orphan plc Announces Positive Data from Peer-Reviewed Study Evaluating the in Vitro Efficacy of Flu-V

First half 2022 earnings released: EPS: UK£0 (vs UK£0.002 in 1H 2021)

Open Orphan plc Reiterates Revenue Guidance for the Full Year of 2022

Open Orphan Plc to Report First Half, 2022 Results on Sep 08, 2022

Open Orphan plc, Annual General Meeting, Jul 05, 2022

Full year 2021 earnings released: EPS: UK£0 (vs UK£0.018 loss in FY 2020)

Open Orphan plc Appoints Martin Gouldstone as Independent Non-Executive Director

Open Orphan plc to Report Fiscal Year 2021 Results on Jun 07, 2022

Less than half of directors are independent

Open Orphan plc Announces Characterisation Study Results in Nature Medicine

Open Orphan plc Appoints Yamin 'Mo' Khan as Chief Executive Officer

First half 2021 earnings released: EPS UK£0.002 (vs UK£0.012 loss in 1H 2020)

Executive Chairman recently bought €352k worth of stock

Full year 2020 earnings released: UK£0.018 loss per share (vs UK£0.034 loss in FY 2019)

New 90-day high: €0.35

Open Orphan plc Announces Ethics Approval for Covid-19 Human Challenge Study

Open Orphan Plc's Subsidiary Venn Life Sciences Announces Contract Extension with Carna Biosciences

New 90-day high: €0.33

Open Orphan plc Announces Contract Renewal with Top-3 Pharmaceutical Client Extending Its Consultancy Services to End of December 2021

Open Orphan plc Announces Board Changes, Effective on December 31, 2020

Open Orphan plc Announces the Signs of A £2.5 Million Contract by hVIVO

New 90-day high: €0.21

New 90-day high: €0.20

Open Orphan plc Announces £4.3 Million Contract to Conduct Human Viral Challenge Study

Open Orphan plc to Report First Half, 2020 Results on Sep 30, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş